As health biotech enterprises in emerging economies move from imitation to innovation, will they become less relevant to local global health priorities?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health Open Access 24 March 2017
-
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators
Health Research Policy and Systems Open Access 06 June 2012
-
Indian vaccine innovation: the case of Shantha Biotechnics
Globalization and Health Open Access 20 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Daar, A.S. et al. Nature 450, 494–496 (2007).
Gustavsen, K. & Hanson, C. Health Aff. 28, 1745–1749 (2009).
Towse, A. & Kettler, H. Bull. World Health Organ. 83, 301–307 (2005).
Grabowski, H. Health Aff. 24, 697–700 (2005).
Ridley, D.B., Grabowski, H.G. & Moe, J.L. Health Aff. 25, 313–324 (2006).
Dentzer, S. Health Aff. 28, w411–w416 (2009).
Lister, S. GlaxoSmithKline to share malaria research in hope of finding a cure. Times Online (2010). <http://www.timesonline.co.uk/tol/news/science/medicine/article6994620.ece>
Frew, S. E. et al. Nat. Biotechnol. 26, 37–53 (2008).
Frew, S.E. et al. Nat. Biotechnol. 25, 403–417 (2007).
Rezaie, R., Frew, S.E. & Sammut, S.M. Nat. Biotechnol. 26, 627–644 (2008).
Al-Bader, S., Frew, S.E. & Essajee, I. Nat. Biotechnol. 27, 427–445 (2009).
<http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/OrphanDrugAct/default.htm> (2009; accessed 10 January 2010).
Frew, S.E., Kettler, H.E. & Singer, P.A. Health Aff. 27, 1029–1041 (2008).
Frew, S., Liu, V. & Singer, P. Health Aff. 28, 1760–1773 (2009).
Acknowledgements
We gratefully acknowledge editorial comments from J. Clark. Also, we are thankful for S. Al-Bader's review of earlier drafts of this paper. C. Gardner provided helpful examples. The McLaughlin-Rotman Centre for Global Health is primarily funded by Genome Canada through the Ontario Genomics Institute, the Grand Challenges in Global Health Initiative (Bill & Melinda Gates Foundation), the Water Efficient Maize for Africa Project (Bill and Melinda Gates Foundation), the Ontario Research Fund and the Canadian Institutes of Health Research (CIHR). Some of our projects also receive funding from the Rockefeller Foundation and BioVentures for Global Health, and through in-kind contributions from Burrill & Company and Wulff Capital. Other matching partners are listed at http://www.mrcglobal.org/. Rahim Rezaie is supported by a doctoral scholarship from the CIHR.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.A.S. has received consulting funds from Merck Frosst Canada and is on the scientific advisory board of the BioVeda II fund in China.
Rights and permissions
About this article
Cite this article
Rezaie, R., Singer, P. Global health or global wealth?. Nat Biotechnol 28, 907–909 (2010). https://doi.org/10.1038/nbt0910-907
Issue Date:
DOI: https://doi.org/10.1038/nbt0910-907
This article is cited by
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health (2017)
-
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators
Health Research Policy and Systems (2012)
-
Indian vaccine innovation: the case of Shantha Biotechnics
Globalization and Health (2011)
